Dual Therapy Improves Psoriasis & PsA: GLP-1s + Ixekizumab Data

A combination therapy approach using GLP-1 receptor agonists alongside ixekizumab is showing promising results for individuals grappling with both psoriatic arthritis (PsA) and psoriasis, according to data presented at the Basic and Clinical Immunology for the Busy Clinician symposium. The findings suggest a potential shift in treatment paradigms, particularly for patients who are also overweight or obese, a condition increasingly common among those with psoriatic disease.

The Interplay of Psoriatic Disease and Weight

Philip J. Mease, MD, of the Swedish Medical Center and the University of Washington, highlighted a concerning trend: nearly half (48%) of patients with PsA are currently classified as obese or overweight. This figure is projected to exceed 50% in the coming years, signaling a growing need to address metabolic factors in the management of these conditions. Individuals with obesity or overweight and psoriasis are at a heightened risk of developing PsA, creating a complex interplay between inflammation, immune response, and metabolic health.

The potential benefits extend beyond weight management. Dr. Mease emphasized that lifestyle interventions – including diet, exercise, improved sleep, pain reduction, and attention to mental health – can positively influence various parameters of psoriatic disease. However, the addition of pharmacological interventions targeting both the immune system and metabolic pathways may offer a more comprehensive approach.

TOGETHER-PsA Study: Combining Ixekizumab and Tirzepatide

The TOGETHER-PsA study, involving 250 patients, compared ixekizumab alone to a combination of ixekizumab plus tirzepatide (Zepbound, Mounjaro. Eli Lilly), a dual GLP-1 and GIP receptor agonist, over a 52-week period. The study’s primary endpoint focused on long-term disease activity, extending beyond the typical 16- or 24-week timeframe often used in clinical trials.

Topline data revealed a notable benefit for the combination therapy compared to ixekizumab monotherapy. Specifically, the combination demonstrated a statistically significant improvement in ACR50 response rates – a measure of clinical improvement in arthritis symptoms. The researchers observed that combining a GLP-1/GIP receptor agonist with ixekizumab significantly increased the likelihood of achieving both a 10% weight loss and an ACR50 response, results that were largely anticipated given the mechanisms of action of the drugs involved.

Beyond Arthritis: Impact on Psoriasis Severity

The positive effects weren’t limited to arthritis symptoms. Patients receiving the combination therapy also exhibited improvements in psoriasis severity, achieving primary endpoint thresholds for PASI 100% response (complete skin clearance) and at least 10% weight loss. This suggests a systemic effect, where addressing metabolic factors can positively influence both the articular and cutaneous manifestations of psoriatic disease.

Dr. Mease noted that these findings challenge conventional approaches to treating psoriatic disease. “Here’s going to challenge us to think more strongly about dual therapy with this type of agent in patients who are obese or overweight and have psoriasis or PsA,” he stated. The data suggest a potential immunomodulatory effect of GLP-1 and GIP receptor agonists, extending beyond their well-established metabolic benefits.

Understanding GLP-1 Receptor Agonists and Ixekizumab

GLP-1 receptor agonists are a class of medications originally developed for the treatment of type 2 diabetes. They work by mimicking the effects of glucagon-like peptide-1, a natural hormone that regulates blood sugar levels, promotes insulin secretion, and suppresses appetite. Recent research suggests these agents may also have anti-inflammatory properties, potentially contributing to their benefits in autoimmune conditions like PsA.

Ixekizumab (Taltz, Eli Lilly) is a monoclonal antibody that selectively blocks the interleukin-17A (IL-17A) cytokine, a key driver of inflammation in psoriasis and PsA. It has demonstrated long-term efficacy and safety in clinical trials, becoming a mainstay in the treatment of these conditions.

What This Means for Patients and Clinicians

The emerging evidence supports a more holistic approach to managing psoriatic disease, recognizing the interconnectedness of inflammation, immune function, and metabolic health. For patients who are overweight or obese, incorporating a GLP-1 receptor agonist into their treatment regimen, alongside established therapies like ixekizumab, may offer a more comprehensive and effective strategy. However, it’s crucial to remember that these findings are still evolving, and further research is needed to fully understand the long-term benefits and risks of this combination approach.

Philip J. Mease, MD, can be reached at [email protected].

Looking Ahead: The field is now focused on larger, longer-term studies to confirm these initial findings and to identify the optimal patient populations who will benefit most from this dual therapy approach. Researchers are also investigating the underlying mechanisms by which GLP-1 receptor agonists exert their anti-inflammatory effects, which could lead to the development of even more targeted and effective treatments for psoriatic disease.